Role of desensitisation for drug hypersensitivity in patients with HIV infection

Drug Safety

Volumn 17, Issue 2, 1997, Pages 119-126

  Carr, Andrew ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; ANTIHISTAMINIC AGENT; ATOVAQUONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; DELAVIRDINE; NEVIRAPINE; PENICILLIN DERIVATIVE; SULFADIAZINE; SULFONAMIDE; THIOACETAZONE;

DESENSITIZATION; DRUG HYPERSENSITIVITY; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MUCOSA INFLAMMATION; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RASH; REVIEW;

EID: 0030821824     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199717020-00004     Document Type: Review

References (50)

1. Mitsuyasu R, Groopmun J, Volherding P. Cutaneous reaction to trimcthoprini-sulfamethoxazole in patients with AIDS and Kaposi's sarcoma [letter]. N Engl J Med 1983; 308: 1535-6
2. Jaffe HS, Ahrams DI. Ammann AJ, et al. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis cystis carinii pneumonia in homosexual men. Lancet 1983; 1: 1109-11
3. Coopman MA, Johnson RA, Platt R. et al. Cutaneous disease and drug reactions in HIV infection. N Eng IJ Med 1493; 328: 1670-4
4. Roujeau J-C, Stern RS, Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85
5. Carr A, Cooper DA, Pathogenesis and management of HIVussocinted drug hypersensitivity. In: Vol herd ing P, Jacohson MA. editors. AIDS Clinical Review 1995/1996. New York: Marcel Dekkcr. 1996: 65-98
6. Schneider MME, Hospelman AIM, J Karel, et al. A controlled trial of trimethoprim-sulfametnoxa/olc or acrosolised pentamidine as primary prophylaxis of Pafumt Hystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327: 1836-41
7. Gordin FM, Simon GL, Wofsy CB, et al. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-9
8. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with irimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm 1988; 22: 43-5
9. Silvestri RC, Jensen WA, Zibrak JD, et al. Pulmonary infiltrates and hypoxacmia in patients with the acquired immune deficiency syndrome re-exposed to trimethoprim-sulfamethoxazole. Am Rev Respir Dis 1987; 136: 1003-4
10. Kovacs JA, Hiementz JW, Macher AM, et al. Pneumocystis ctirinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100: 66-71
11. Jick J, Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982; 4:426-8
12. Lau WK, Young LS, Trimcthoprini-sulfamethoxuzole treatment of Pneumocystis carinii pneumonia in adults. N fengl J Med 1976; 295: 716-8
13. Winston DJ, Lau WK, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pnenmtcystis curinii pneumonia. Ann Intern Med 1980; 92: 762-9
14. Sattler FR, Cowan R, Nielscn DM, et al. Trimethoprim-sulfamethoxazole compared with peniamidine for treatment of Pneunucystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective non-crossover study. Ann Intern Med 1988; 109:280-7
15. Wharton JM, Colemun DL, Wofsy CB, et al. Trimethopvimsulphamethoxazole or pentamidine for Pneumttrystis carinii pneumonia in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 105: 37-44
16. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trincthoprim-dapsone. N Engl J Med 1990; 323:776-82
17. Carr A, Swanson C, Penny R, et al. Clinical and laboratory markers of hypcrsensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia AIDS. J Infect Dis 1993; 167: 180-5
18. Hughes W, Leinmg G, Kramer F et al. Comparison of atovuquone (566C80) with trimethoprim-sulfamcthoxazole lor the treatment of Pneumocystis carinii pneumonitis in patienls with AIDS. N Engl J Med 1993; 328: 1521-7
19. CDC, Recommendations for prophylaxis againsl Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992; 41: 1-11
20. Carr A, Tindall B, Brew B, et al. Low dose trimethoprim-sulfamcthoxuzole prophylaxis against loxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117: 106-11
21. Curr A, Tindull B, Penny R, et al. Multiple drug hypersensitivity in putienls with HIV diseuse [letter]. AIDS 1993; 7: 1532-3
22. C'arr A, Vusak E, Munro V, et al. Immunonistologic a I assessment of eutuneous drug hypersensitivity in putienis with HIV infection. Clin Exp Immunol 1994; 97: 250-3
23. Greenberger PA, Patlerson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1987; 79: 484-8
24. Aguilar X, Ruix J, Clotet B, et al. The use of corlicosleroids in the control of adverse effects of coirimoxuzole in AIDS patients suffering with PCP [letter]. AIDS 1991; 5: 777-8
25. Hennessy S, Strom BL, Berlin JA, et al. Predicting cutaneous hypcrsensilivily reactions to cotrimoxazole in HlV-infcclcd individuals receiving primary Pneumocystis carinni pneumonia prophylaxis. J Gen Intern Med 1995; 10: 380-6
26. Montuner JSG, Lawson LM, Levitt N, et al. Corticosteroids prevent curly deterioration in putienis with moderately severe Pneunwcystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1990; 113: 14-20
27. Gagnon S, Boota AM, Fischl MA, et al. Corticosleroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a douhle blind, placebo-controlled trial. N Engl J Med 1990; 323: 1444-50
28. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323: 1451-7
29. Clark DW, Variability in drug acetylalion and oxidation: therapeutic implications. Drugs 1985; 29: 342-75
30. Centers for Disease Control. Guidelines for prophylaxis against Pneumttcystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992; 41: RR-4
31. Shafer RW, Seitzmann PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprini-sulfumelhoxazole in AIDS patients with previous allergic reactions. J Aequir Immune Defle Syndr 1989; 2: 389-93
32. Carr A, Penny R, Cooper DA. Efficacy and sufety of rechallenge with low dose trimethoprim-sulphanicthoxuzole of previously hypersensitive HIV-infected putienis. AIDS 1993; 7: 65-71
33. Gluckslein D, Ruskin J, Nielsen D. Oral desensitisution to trimethoprim-sulfaincthoxazule in hyperscasitive AIDS palients: utility in trimethoprim-sulphumclhoxuzole pniphylaxis of Pnfumwvstis ctirinii pneumonia [abstract]. 4th International Conference on AIDS: 1988 Jun 20-24; Stockholm, A7176
34. Finegold I. Oral desensilisation to trimethoprim-sulfaineihoxazole in a patient with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1986; 78: 905-8
35. Ahsar N, Danashevar H, Bcall G. Desensitisation to trimethoprirn-sulfamethoxazole in HIV-intcctcd patients. J Allergy Clin Immunol 1994; 93: 1001-5
36. Gilquin J. Piketty C, Kazaichkinc MD. Efficacy and safety of Irimclhoprim-sulfamcthoxazolc deserialisation in HIV-infectcd patients [abstract]. 10th International Conference on AIDS: 1994 Aug 7-12; Yokohama. PB0616
37. Belehi-Hemandcx J, Espinosa-Parra FJ. Management of adverse rvactions to prophylactic trimcthoprim-sulphamethoxazolc in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol 1996; 76: 355-8
38. Nguyen MT, Weiss PJ, Wallace MR. Two-day oral desensitization 10 trimelhoprim-sulphamcthoxazole in HIV-intcctcd patients. AIDS 1995; 9: 573-5
39. Bachmcycr C, Salmon O, Gucrin C, et al. Trimethoprim-sulphamethoxaxole desensitisation in HIV-intecled patients [letter|. AIDS 1995; 9: 299-300
40. Piketty C, Gilquin J, Kazatehkine MD. Efficacy and safety of desensilization to trirnethoprim-sulfarnclhoxa/olc in human immunodeficiency virus-infected patients [letter]. J Infect Dis 1995; 172: 611
41. Gluckslein D, Ruskin J, Rapid oral descnsitizauon to trimethoprim-sulfamclhoxazolc (TMP-SMX): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995; 20: 849-53
42. Bissuel F, Cotte L, Crapanne JB, et al. Trimethoprim-sulphamethoxazole in 20 previously allergic HIV-infected patients. AIDS 1995; 9: 407-8
43. Tenant-Flowers M, Boyle M. Carey D, et al. Sulphadiazine descnsiiisation in patients with AIDS and cerebral toxoplasmosis AIDS 1991; 5: 311-5
44. Bell ET, Tapper ML, PolIeck AA, Sulphiidiazine desensitisation in AIDS patients [lettcr]. Lancet 1985; 1: 163
45. Mctroka CL, Lewis NJ, Jacobus DP. Desensilizution to dapsone in HIV-positive patients [letter]. JAMA 1992; 267: 512
46. Canines E, Guennonprez G, Lecomic C, et al. Efficacy and safely of descnsitization with .sulfamelhoxazok and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus. Arch Dermatol 1997; 133: 465-9
47. Dohn M, Frame P, Becker S, et al. ACTG 268 trial: gradual introduction of triniethoprim-sulfamcthoxa/ole as primary prophylaxis for Penumocystis carinni pneumonia [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1997 Jan 29-Feb 2: Washington. DC
48. Carr A, Vella S, de Joug MD, et al. A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infecled patients. AIDS 1996; 10:635-41
49. Carr A, Penny R, Cooper DA. Allergy and desensilization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS). J Allergy Clin Immunol I993; 91: 683-5
50. Canines E, Guermonprez G, Winter C, et al. A life-threatening reaction to trimcthoprim-sulfamcthoxazole dcscnsitization in an HIV-infeeted patient [letter]. Clin Infect Dis 1996; 23: 1313-4